沙利度胺联合XELOX方案治疗晚期结直肠癌42例

Clinical Study of XELOX plus Thalidomide for Treating Advanced Colorectal Cancers in 42 Cases

目的观察沙利度胺联合XELOX方案对晚期结直肠癌的疗效及不良反应。方法 42例晚期结直肠癌患者口服沙利度胺200mg/d,服用1～10d;同时采用奥沙利铂130mg/m2,1d,静脉滴注2h;卡培他滨2000mg/(m2·d),分早晚2次,餐后30min口服,1～14d。21d为1个周期,2个周期后评价疗效。近期疗效按RECIST标准评价。结果 42例中完全缓解2例(4.76%),部分缓解20例(47.62%),疾病稳定10例(23.81%),进展10例(23.81%);有效率为52.38%;中位生存期为13.6月;疾病进展时间为7.2月。主要不良反应为神经系统毒性、白细胞降低和手足综合征。结论沙利度胺联合XELOX方案治疗晚期结直肠癌疗效肯定,安全性较好。

Objective To observe the therapeutic effects and adverse reactions of thalidomide combined with capecitabine and oxaliplatin（XELOX） in the treatment of advanced colorectal cancers.Methods Forty-two patients with advanced colorectal cancers received thalidomide [200 mg /（m^2 · d）,on 1-10 d] and the chemotherapeutic regimen oxaliplatin 130 mg /m2 by intravenous drip for 2 h on 1 d,capecitabine 2 000 mg /m^2,taking orally at 30 min after meal,twice a day,on 1-14 d,3 weeks as one circle.The efficacy was evaluated after 2 circles.Results Among 42 cases,2 cases（4.76%） achieved complete response（CR）,20 cases（47.62%） partial response（PR）,10 cases（23.81%） stable disease and 10 cases（23.81%） progression disease（PD）.The overall response rate was 52.38%.MST was 13.6 months and TTP was 7.2 months.The major toxicity included neurotoxicity,leucopenia and hand-foot syndrome.Conclusion The regimen of thalidomide combined XELOX is effective and tolerable in the treatment of advanced colorectal cancers.